Miyagawa H, Kamioka N, Kohara H, Yuube R, Takahashi T, Nakatoh H, Kawada M, Utsunomiya T, Izumiyama F, Akimori T
Dept. of Internal Medicine, Kouchi Municipal Hospital of Aki.
Gan To Kagaku Ryoho. 1993 Nov;20(14):2211-5.
A 59-year-old male with liver cirrhosis was admitted to our hospital for further examination of general fatigue. A huge tumor was found in the right lobe of his liver with abdominal ultrasonography and computed tomography (CT). The titers of serum AFP (14,055 ng/ml) and PIVKA-II (more than 50.0 AU/ml) were extremely high. A tumor embolus was observed in the portal vein with abdominal angiography. According to these findings, he was diagnosed as having advanced hepatocellular carcinoma (HCC). He was treated by oral administration of UFT (600 mg/day) as an unresectable case of HCC. Three months later, the clinical symptoms were greatly improved and HCC was almost diminished with abdominal ultrasonography and CT, although a small tumor embolus was found by angiography. The titers of AFP and PIVKA-II were reduced to the normal range. This case suggests the clinical effectiveness of UFT for the treatment of HCC.
一名59岁的肝硬化男性因全身乏力入院接受进一步检查。通过腹部超声和计算机断层扫描(CT)发现其肝脏右叶有一个巨大肿瘤。血清甲胎蛋白(AFP)水平(14,055纳克/毫升)和异常凝血酶原(PIVKA-II)水平(超过50.0 AU/毫升)极高。腹部血管造影显示门静脉有肿瘤栓子。根据这些检查结果,他被诊断为晚期肝细胞癌(HCC)。作为无法切除的HCC病例,他接受了口服优福定(UFT,600毫克/天)治疗。三个月后,临床症状明显改善,腹部超声和CT检查显示HCC几乎消失,尽管血管造影发现有一个小的肿瘤栓子。AFP和PIVKA-II水平降至正常范围。该病例表明优福定对HCC治疗具有临床有效性。